Healthcare / Medical DevicesSaudi
$24.19
+1.47 (+6.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-1.7M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$60M
P/E
30.6x
↑EV/EBITDA
13.6x
↑ROE
6.4%
↑Gross Margin
38.2%
↓Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+6.3%
FCF CAGR
—
FCF margin
-34.8%
FCF / Net income
-3.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $20.4M · net income $2.0M · FCF $-7.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $20.4M | $20.4M | $19.9M | $18.0M |
| Net Income | $2.0M | $2.0M | $4.8M | $4.2M |
| EBITDA | $3.8M | $3.8M | $6.3M | $5.6M |
| EPS | — | — | 1.91 | 1.66 |
| Gross Margin | 38.2% | 38.2% | 41.8% | 45.3% |
| Operating Margin | 13.0% | 13.0% | 26.4% | 24.4% |
| Net Margin | 9.7% | 9.7% | 24.1% | 23.1% |
| Balance Sheet | ||||
| Debt/Equity | 0.05 | 0.05 | 0.06 | 0.13 |
| Current Ratio | 10.26 | 10.26 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-7.1M | $-7.1M | $5.3M | $-1.7M |
| Returns | ||||
| ROE | 6.4% | 6.4% | 16.5% | 28.9% |
| Valuation | ||||
| P/E | 30.62 | 30.62 | 19.11 | — |
| EV/EBITDA | 13.55 | 13.55 | 11.83 | — |
| P/B | 1.96 | 1.96 | 3.16 | — |
| Growth & Yield | ||||
| Revenue Growth | 2.6% | 2.6% | 10.1% | — |
| EPS Growth | — | — | 14.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-36.3%
Start / end P/E
n/dx → n/dx
EPS bridge
1.91 → n/d
Residual
-36.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.